Overview
STAR SPORTS MED (1609)
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such a...
- Open
- 55.050
- High
- 55.050
- Low
- 49.180
- Prev. Close
- 52.500
- Volume
- 120.10K
- Turnover
- 6.13M
- Avg Price
- 51.014
- Bid/Ask Ratio
- -94.59%
- Amplitude
- 11.18%
- 52wk High
- 299.000
- Volume Ratio
- 2.68
- Turnover Ratio
- 0.22%
- 52wk Low
- 47.260
- HK Mkt Cap
- 2.87B
- Market CapHKD
- 2.87B
- P/ETTM
- 19.56
- P/EDynamic
- 45.43
- P/EStatic
- --
- EPSTTM
- 2.68
- EPSDynamic
- 1.16
- EPSStatic
- --
- BVPS
- 27.46
- P/B
- 1.91
- HK Shares
- 54.60M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 54.60M
- Min lot size
- 50
- Currency
- HKD
Daily Events
- Nov, 16
Star Sports Medicine (1609.HK) reversed early gains to close down 6.1% at HK$49.30, having touched HK$54.05 at 9:31 BJ before a steady afternoon slide to the session low, as the IPO cornerstone investors' lock-up approached expiry; volume was thin at 117,050 shares worth HK$5.96 million, a 0.21% turnover rate. The stock had already fallen 22.69% over the prior week and printed a 52-week low of HK$47.26 on 3 November, leaving it more than 80% below its HK$299 peak on 4 May and down over 70% year-to-date. It now sits below its 20-day average of HK$52.87 and about 45% below its 60-day average of HK$89.50. The company has filed several next-day disclosure returns on share buybacks and shareholders approved a 2026 incentive scheme at an extraordinary meeting, while the HK$2.89 billion market value carries a 19.73x PE and 1.93x PB; though buybacks at such low turnover have so far absorbed little of the selling.
- Nov, 13
Shares fell 4.63% to HK$52.55 as the approaching expiry of IPO cornerstone lock-ups weighed on sentiment, with the stock spiking to HK$56.00 in the morning session before sliding to a HK$52.05 low at 14:51 BJ and settling near the day's trough on 63,050 shares worth HK$3.36m, a thin 0.12% turnover. The move extends a 22.69% weekly decline and follows a HK$47.26 52-week low on 3 November; at HK$52.55 the price sits 82.42% below the HK$299 peak of 4 May and down 75.56% year-to-date, beneath both MA20 (HK$53.70) and MA60 (HK$91.06). The company has repeatedly disclosed share buybacks in HKEX next-day returns and shareholders approved the 2026 incentive scheme, with market capitalisation of about HK$2.87bn, PE 19.58x and PB 1.91x. Though the buyback scale remains small relative to market value.
- Nov, 10
After sliding to a 52-week low of HK$47.26 on 3 November, Star Sports Medicine opened at HK$51.05, its session low, pushed to HK$53.75 at 13:29, faded to HK$51.80 late and settled at HK$52.55, up about 3.0%, on just 86,850 shares and HK$4.56 million turnover (0.15% turnover rate), a spike-then-fade pattern. The move followed a week in which roughly 2.92 million cornerstone shares reach lock-up expiry this Thursday, alongside single-day declines of 7%-9% in late October; the company has bought back stock repeatedly since 27 October, including 10,000 shares for HK$483,900 on 3 November, absorbing part of the supply. The price remains below its MA20 of HK$55.57 and MA60 of HK$96.01, down 75.56% year to date and 82.42% below the HK$299 high of 4 May, at 19.59x PE. Though thin volume leaves the support untested.
- Nov, 9
Star Sports Medicine reversed early gains, gapping up to HK$55.40 at the open before fading to close at HK$51.45, down 2.0% from the previous HK$52.50, with the afternoon session touching HK$50.10 on only 115,350 shares worth about HK$5.94 million, a 0.21% turnover rate. The overhang is concentrated on 2.92 million cornerstone shares whose lock-up expires Thursday; the stock set a 52-week low of HK$47.26 on November 3, sits 82.8% below its 52-week high and is down 76.1% year to date, still under its MA20 of HK$56.14. Buybacks have run since October 27, including 10,000 shares for HK$483,900 on November 3, offering limited support. At 19.18x PE and HK$2.81 billion market cap, though, whether repurchases can absorb the unlock supply remains open.
- Nov, 6
With the IPO cornerstone investors' lock-up expiring this Thursday and roughly 2.92 million shares due to become tradable, the stock closed at HK$52.70, down 3.9% from the prior close of HK$54.85, tracing a gap-up-then-fade pattern: it opened at HK$55.85, printed HK$55.60 at 09:30 and slid to HK$50.70 in the morning session, on only 98,500 shares and HK$5.21 million turnover, a 0.16% turnover rate. Buybacks since late October, including 17,000 shares for HK$921,000 on Oct 28 and another 10,000 shares for about HK$483,900 on Nov 3, have not reversed the slide. The shares are down 75.3% year to date and 82.3% below the HK$299 52-week high of May 4, sitting just 12.3% above the HK$47.26 low touched on Nov 3 and below both the MA20 of HK$56.77 and MA60 of HK$99.01. Still, it stood as the largest domestic sports-medicine implant supplier in 2024 with a 6.5% share, at a PE of 19.8x.
News
PUBT · Star Sports Medicine Files HKEX Next-Day Return Disclosing Share Buyback
Market Movers · Star Sports Med drops 6% in Hong Kong trading
PUBT · Star Sports Medicine Reports Share Buyback in HKEX Next Day Disclosure Return
PUBT · Star Sports Medicine Discloses Share Buyback in HKEX Filing
Weekly Review · Weekly Recap | STAR SPORTS MED +2.14%, lock-up week turns volatile
Market Movers · Star Sports Med drops 9%
